Biogen Inc. (BIIB), based in Cambridge, Massachusetts, has a market capitalization of approximately $33.3 billion. Founded in 1978, the biotechnology company discovers, develops, manufactures, and commercializes innovative medicines for neurological, neurodegenerative, autoimmune, and rare diseases, leveraging scientific research to improve patient outcomes and drive long-term growth.
BIIB is set to report its Q3 earnings on Wednesday, October 28, 2026, before the market opens. Ahead of the release, analysts expect the company to report diluted EPS of $2.10, down 56.3% from $4.81 in the year-ago quarter. That said, BIIB has exceeded Wall Street’s EPS estimates in each of the past four quarters, highlighting its consistent earnings performance.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts expect BIIB to report EPS of $12.41, down 18.8% from $15.28 in fiscal 2025. However, BIIB’s EPS is projected to grow 30.1% year over year to $16.15 in fiscal 2027.
www.barchart.comBIIB stock has risen 56.5% over the past 52 weeks, substantially outperforming both the S&P 500 Index ($SPX), which gained 19.2%, and the State Street Health Care Select Sector SPDR ETF (XLV), which gained 21% over the same period.
www.barchart.comBiogen shares jumped 3.5% in premarket trading on Oct. 12, after JPMorgan Chase (JPM) upgraded the stock to “Overweight” from “Neutral” and raised its price target from $210 to $300. The upgrade reflected growing optimism about Biogen’s drug pipeline, including upcoming Phase 3 data for felzartamab and litifilimab, and the potential for pipeline progress to accelerate earnings growth through 2030.
Adding to this positive outlook, on September 16, 2026, Biogen and Eisai Co., Ltd. (ESALF) announced that Japan had approved LEQEMBI Pen, a subcutaneous formulation of Leqembi, for the treatment of early Alzheimer’s disease. The approval expands the drug’s administration options and could improve convenience for patients, supporting its commercial potential. Together, the regulatory milestone and growing optimism about Biogen’s pipeline strengthen the company’s outlook, although the financial impact will depend on commercial adoption and clinical progress.
Analysts remain cautiously bullish on BIIB, with a consensus “Moderate Buy” rating. Of the 34 analysts covering the stock, 20 recommend a “Strong Buy,” two suggest a “Moderate Buy,” and 12 rate it a “Hold.” The average analyst price target of $239.19 represents a 4.3% premium to the current share price.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Why It’s Time to Load Up on Marvell Stock Dear TSMC Stock Fans, Circle Oct. 15 on Your Calendar Dear Accenture Stock Fans, Mark Your Calendars for Oct. 14 Nasdaq Futures Slip as Chip Stocks Extend Slide; Big Bank Earnings on Tap